All In Biotech

Drug Trial Radar · NCT07139431

A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution

A Study to Evaluate the Cellular Distribution of [89Zr]-Oxine-NCR100 Injection in the Treatment of Subjects With Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Aug 29, 2025

Primary completion

Mar 6, 2026

Study completion Apr 21, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical study is to evaluate the biodistribution of \[89Zr\]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the injection site and various organs or tissues. It is a single-dose, open-label study in adult KOA subjects.

Conditions

  • KOA

Interventions

  • NCR100Biological

    Subjects will receive a single injection of NCR100

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Standardized Uptake Values (SUV) and %IDTime frame: Day2, Day8,Day12,and Day22

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.